Benchmarks
View scores and output across OCR models spanning many document categories.
Want to run these evals on your own documents?
Talk to SalesBD 2021 ESG Report
Introduction
Climate change
Product impact
Responsible supply chain
Healthy workforce and communities
Transparency
Appendices
9
About our business
FY21 revenue by region
54%
United States
22%
Europe
7%
China
18%
Rest of world
FY21 revenue by segment
Values in this exhibit reflect rounded numbers in billions of dollars
$20.2
Total BD revenue
| BD Medical | $9.5 |
| Medication Delivery Systems | $4.1 |
| Medication Management Solutions | $2.4 |
| Diabetes Care* | $1.2 |
| Pharmaceutical Systems | $1.8 |
| BD Life Sciences | $6.5 |
| Integrated Diagnostics Solutions | $5.2 |
| Biosciences | $1.3 |
| BD Interventional | $4.2 |
| Peripheral Intervention | $1.7 |
| Surgery | $1.3 |
| Urology and Critical Care | $1.2 |
*On April 1, 2022, BD executed the spin of its Diabetes Care business, which is now a stand-alone and publicly traded company named Embecta Corp. (NASDAQ: EMBC).